eligibility_summary
Eligible: adults (≥18) with WHO-defined diffuse large B‑cell lymphoma, no prior chemotherapy, able to understand/sign consent and adhere to visits, life expectancy ≥3 months. Exclude: active/uncontrolled infection needing systemic therapy within 14 days, unstable severe systemic disease (cardiac, liver, kidney, metabolic) needing treatment, pregnant or lactating.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm induction regimen Pola‑ZR2P for previously untreated DLBCL. Drugs/mechanisms: Polatuzumab vedotin (antibody‑drug conjugate to CD79b, delivers MMAE to disrupt microtubules and induce B‑cell apoptosis), Zanubrutinib (oral small‑molecule covalent BTK inhibitor, blocks B‑cell receptor signaling), Rituximab (anti‑CD20 monoclonal antibody, ADCC/CDC and direct apoptosis of B cells), Lenalidomide (oral IMiD, cereblon‑mediated IKZF1/3 degradation, enhances T/NK cytotoxicity, modulates cytokines/angiogenesis), Prednisone (oral corticosteroid, lympholytic apoptosis, anti‑inflammatory). Targets/pathways: malignant B cells (CD79b, CD20), BTK/BCR–NF‑κB signaling, microtubules, cereblon–IKZF1/3 axis, glucocorticoid receptor, tumor immune microenvironment.